Amicus Therapeutics to acquire Celenex and 10 gene therapy programs for $100m.

Amicus Therapeutics, a global, patient-centric biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases, agreed to acquire Celenex, a private, clinical stage gene therapy company, for $100m. “The in-licensing and acquisition of these gene therapy programs provides an extraordinary opportunity to transform the lives of thousands of children living with some of the most devastating forms of lysosomal storage disorders, for which there are virtually no treatment options today,” John F. Crowley, Amicus Therapeutics Chairman and CEO.